SG11201502937PA - COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES - Google Patents
COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULESInfo
- Publication number
- SG11201502937PA SG11201502937PA SG11201502937PA SG11201502937PA SG11201502937PA SG 11201502937P A SG11201502937P A SG 11201502937PA SG 11201502937P A SG11201502937P A SG 11201502937PA SG 11201502937P A SG11201502937P A SG 11201502937PA SG 11201502937P A SG11201502937P A SG 11201502937PA
- Authority
- SG
- Singapore
- Prior art keywords
- psl
- pseudomonas
- binding molecules
- combination therapies
- pcrv binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261723192P | 2012-11-06 | 2012-11-06 | |
PCT/US2013/068609 WO2014074528A2 (fr) | 2012-11-06 | 2013-11-06 | Polythérapies à l'aide de molécules de liaison anti-pseudomonas psl et pcrv |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201502937PA true SG11201502937PA (en) | 2015-06-29 |
Family
ID=50685302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201502937PA SG11201502937PA (en) | 2012-11-06 | 2013-11-06 | COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES |
Country Status (11)
Country | Link |
---|---|
US (1) | US20150284450A1 (fr) |
EP (1) | EP2917236A2 (fr) |
JP (1) | JP2015535005A (fr) |
KR (1) | KR20150082367A (fr) |
CN (1) | CN104995209A (fr) |
AU (1) | AU2013341349A1 (fr) |
BR (1) | BR112015010240A2 (fr) |
CA (1) | CA2888211A1 (fr) |
MX (1) | MX2015005719A (fr) |
SG (1) | SG11201502937PA (fr) |
WO (1) | WO2014074528A2 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3385280A1 (fr) | 2011-06-10 | 2018-10-10 | MedImmune Limited | Molécules de liaison anti-psl de pseudomonas et leurs utilisations |
RS60920B1 (sr) * | 2011-11-07 | 2020-11-30 | Medimmune Ltd | Kombinovane terapije primenom anti-pseudomonas psl i pcrv vezujućih molekula |
TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
BR112017023378A2 (pt) * | 2015-05-01 | 2018-07-24 | Inhibrx Lp | moléculas de direcionamento do sistema de secreção do tipo iii |
EP3798232A1 (fr) | 2015-07-16 | 2021-03-31 | Inhibrx, Inc. | Protéines de fusion se liant à dr5 multivalentes et multispécifiques |
WO2017095744A1 (fr) | 2015-11-30 | 2017-06-08 | Medimmune, Llc | Procédé de prévention ou de traitement d'une pneumonie nosocomiale |
CA3023094A1 (fr) * | 2016-05-05 | 2017-11-09 | The Trustees Of The University Of Pennsylvania | Constructions d'anticorps anti-adn pour utilisation contre pseudomonas aeruginosa |
EP3655028A4 (fr) * | 2017-10-02 | 2021-06-09 | Aridis Pharmaceuticals, Inc. | Compositions et méthodes contre des infections par p. aeruginosa |
GB201816553D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
GB201816554D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
WO2020252029A1 (fr) | 2019-06-11 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation |
KR20220029710A (ko) * | 2019-07-09 | 2022-03-08 | 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 | 슈도모나스 pcrv를 특이적으로 인식하는 항체 및 이의 용도 |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
CN114072145A (zh) * | 2020-06-01 | 2022-02-18 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别假单胞菌pcrv的抗体及其用途 |
JP2023537042A (ja) * | 2020-08-07 | 2023-08-30 | 北京三▲諾▼佳邑生物技▲術▼有限▲責▼任公司 | シュードモナス属Pslを特異的に認識する抗体およびその使用 |
CN116621987A (zh) * | 2020-11-18 | 2023-08-22 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别假单胞菌pcrv或psl抗原的抗体组合以及双特异性抗体 |
WO2024003103A1 (fr) | 2022-06-29 | 2024-01-04 | Astrazeneca Ab | Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3841360B2 (ja) * | 1996-06-24 | 2006-11-01 | ツェットエルベー・ベリング・アクチェンゲゼルシャフト | リーサスd抗原に対して特異性を有する抗原結合性構造を形成し得るポリペプチド、それらをコードするdna及びその調製方法並びに使用 |
GB0107658D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
PL1656391T3 (pl) * | 2003-08-13 | 2011-03-31 | Pfizer Prod Inc | Zmodyfikowane ludzkie przeciwciała IGF-1R |
US7312320B2 (en) * | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
EP1801208A4 (fr) * | 2004-09-06 | 2009-04-01 | Kirin Pharma Kk | Anticorps anti-a33 |
EP1838854B1 (fr) * | 2004-12-15 | 2012-10-31 | Janssen Alzheimer Immunotherapy | Anticorps reconnaissant le peptide beta amyloide |
US7910703B2 (en) * | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
US20110033476A1 (en) * | 2007-11-12 | 2011-02-10 | Theraclone Sciences Inc. | Compositions and methods for the therapy and diagnosis of influenza |
CA2706732A1 (fr) * | 2007-11-30 | 2009-06-11 | Kalobios Pharmaceuticals, Inc. | Anticorps diriges contre l'antigene pcrv de pseudomonas aeruginosa |
US9758594B2 (en) * | 2008-04-25 | 2017-09-12 | Kyowa Hakko Kirin Co., Ltd. | Stable multivalent antibody |
WO2010054010A1 (fr) * | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anticorps anti-dll4 et utilisations associées |
BR112013020086B1 (pt) * | 2011-02-08 | 2020-12-08 | Medimmune, Llc | Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina |
EP3385280A1 (fr) * | 2011-06-10 | 2018-10-10 | MedImmune Limited | Molécules de liaison anti-psl de pseudomonas et leurs utilisations |
RS60920B1 (sr) * | 2011-11-07 | 2020-11-30 | Medimmune Ltd | Kombinovane terapije primenom anti-pseudomonas psl i pcrv vezujućih molekula |
-
2013
- 2013-11-06 JP JP2015540877A patent/JP2015535005A/ja active Pending
- 2013-11-06 AU AU2013341349A patent/AU2013341349A1/en not_active Abandoned
- 2013-11-06 US US14/440,215 patent/US20150284450A1/en not_active Abandoned
- 2013-11-06 CN CN201380058109.4A patent/CN104995209A/zh active Pending
- 2013-11-06 EP EP13853854.1A patent/EP2917236A2/fr not_active Withdrawn
- 2013-11-06 MX MX2015005719A patent/MX2015005719A/es unknown
- 2013-11-06 SG SG11201502937PA patent/SG11201502937PA/en unknown
- 2013-11-06 BR BR112015010240A patent/BR112015010240A2/pt not_active IP Right Cessation
- 2013-11-06 KR KR1020157014108A patent/KR20150082367A/ko not_active Application Discontinuation
- 2013-11-06 CA CA2888211A patent/CA2888211A1/fr not_active Abandoned
- 2013-11-06 WO PCT/US2013/068609 patent/WO2014074528A2/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2917236A2 (fr) | 2015-09-16 |
MX2015005719A (es) | 2016-01-12 |
AU2013341349A1 (en) | 2015-05-21 |
WO2014074528A3 (fr) | 2014-07-03 |
KR20150082367A (ko) | 2015-07-15 |
US20150284450A1 (en) | 2015-10-08 |
WO2014074528A2 (fr) | 2014-05-15 |
WO2014074528A8 (fr) | 2015-05-21 |
BR112015010240A2 (pt) | 2017-08-22 |
CN104995209A (zh) | 2015-10-21 |
CA2888211A1 (fr) | 2014-05-15 |
AU2013341349A8 (en) | 2015-12-03 |
JP2015535005A (ja) | 2015-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201502937PA (en) | COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES | |
IL260189A (en) | Communicating molecules for bcma and cd3 | |
HK1201453A1 (en) | Combination therapies using anti- pseudomonas psl and pcrv binding molecules psl pcrv | |
KR101581655B9 (ko) | 세포 내 관통능을 가지고 rna 간섭을 유도하는 핵산 분자 및 그 용도 | |
HRP20180458T1 (hr) | Molekule koje vežu anti-pseudomonas psl i njihova uporaba | |
EP2931319A4 (fr) | Molécules d'acide nucléique modifiées et leurs utilisations | |
EP2585595B8 (fr) | Molécules d'arn et leurs utilisations | |
ZA201307302B (en) | Cd37-binding molecules and immunoconjugates thereof | |
PL3650125T3 (pl) | Rozpylacz cieczy i sposoby | |
ZA201300930B (en) | St-246 liquid formulations and methods | |
GB201219487D0 (en) | Anti-S100A4 antibody molecules and their uses | |
HK1211055A1 (en) | New cell-specifically active nucleotide molecules and application kit for the application thereof | |
GB201015790D0 (en) | Thrombin-binding antibody molecules and uses thereof | |
AU2011904605A0 (en) | Adiposity-modulating molecules and uses therefor | |
AU2012904469A0 (en) | Wastewater refinery | |
AP2014007497A0 (en) | Binding molecules for BCMA and CD3 | |
GB201014117D0 (en) | Assay molecules | |
GB201014118D0 (en) | Assay molecules |